INTRODUCTION
Dendritic cells (DCs) have a pivotal role in immune homeostasis, marshaling immunity against pathogens, while maintaining tolerance to commensals. The nasal associated lymphoid tissue (NALT) serves as a site for the induction of nasal, 1,2 pharyngeal, 3 respiratory, 4 oral, 2 gastrointestinal, 5, 6 genitourinary, 7, 8 and systemic 9 immunity. Therefore, it follows that the nose should contain a significant population of DCs capable of priming and disseminating immune responses. However, nasal DCs have not yet been characterized and are the focus of the present study.
The murine NALT consist of paired lymphoid structures, resting on the nasal surface of the soft palate on either side of the nasal septum. [10] [11] [12] The NALT is covered by follicleassociated epithelium 13 interspersed with M cells, [14] [15] [16] goblet cells, 17, 18 and intra-epithelial lymphocytes. 19 Within the NALT, B cells predominate over T cells at steady state, 7, 20, 21 with IgD þ and IgM þ B cells constitutively present and IgA þ B cells readily inducible following intranasal (i.n.) vaccination. 8, 22 Among T cells, Th0 CD4 þ T cells, CD8 þ aa, CD8 þ ab, and CD8 þ gd T cells have been described in the NALT, with CD4 þ T cells predominating over CD8 þ T cells at steady state. 19, 23, 24 Although structural similarities between the NALT and Peyer's patches are noted, 21, 23 important differences exist with regards to development 13 and lymphocyte homing. 25, 26 DCs initiate the adaptive immune response. 27 Since the initial description of DCs as ''CD11c þ cells'', we have come to recognize the complexity and lineage diversity of DCs in various tissues. 28, 29 Among the nasal DCs, although studies have alluded to CD11c þ cells in the NALT, 20, 30 there are no descriptions of DC phenotype, subsets, or function.
Here, by using a variety of assays, we have defined the morphology, phenotype, ontogeny, and function of mouse nasal DCs. In doing so, we demonstrate the complexity of nasal DCs and their behavior in the face of inflammatory stimuli such as lipopolysaccharide (LPS). In addition, we have examined putative DC subsets in surgically resected human nasopharyngeal tissue from normal volunteers as well as patients with 1 chronic rhinosinusitis (CRS). The data presented herein are the first description of nasal DCs and will inform the design of novel i.n. vaccines for prevention and treatment of diseases.
RESULTS

Morphology of nasal DCs in mice
The NALT were identified on the nasal surface of the palate, between the incisors and first molar teeth as tridimensional, oval structures on hematoxylin and eosin staining. Higher magnification ( Â 400) revealed aggregates of mononuclear cells, populating the NALT (Figure 1a) . To further study these mononuclear cells, nasal cryosections were stained with combinations of fluorescent antibodies identifying putative CD11c þ DCs, CD3 þ T cells, and B220 þ B cells. Respective isotype controls confirmed the specificity of staining (data not shown). Distinct T and B areas were noted in the NALT as reported previously. 30 Notably, DCs were predominantly seen in the T-cell areas or in the periphery of the NALT (Figure 1b) . Three-dimensional imaging using two-photon microscopy revealed a high density of CD11c-eYFP þ cells uniformly distributed on the NALT surface ( Figure 1c) . The majority of CD11c-eYFP þ cells were embedded among collagen fibers visualized by second harmonic generation and displayed numerous dendrites (Supplementary Figure S1 online). However, on deeper imaging through the NALT, CD11c-eYFP þ cells reduced in frequency and showed a less ruffled and condensed morphology (data not shown). To further study the peripherally distributed CD11c þ cells, nasal sections were double-labeled with anti-mouse keratin 18 and CD11c. A dense network of CD11c þ cells was found subjacent to the epithelium ( Figure 1d) . Fortuitously, in some of the sections we detected that nasal DCs were extending dendrites across the nasal epithelium, into the lumen of the nose ( Figure 1d ). As extension of DC dendrites was observed infrequently, we are unable to quantify this in the present study. We next studied the association of nasal CD11c þ cells with blood vessels (anti-PECAM-1) and lymphatic channels (anti-LYVE-1), and found nasal DCs clustering with lymphatic vessels in the posterior aspects of the NALT (Figure 1e ) as well as the blood vessels distributed throughout the NALT (Figure 1f ). Thus, a high density of putative DCs, positioned to sample the airway antigens, was noted within the murine nose.
Phenotypic characterization of murine nasal DCs identifies distinct subsets of myeloid DCs
Using multi-parameter flow cytometry, we first examined DCs from the entire nose and gated on live, CD45 þ , lymphocyte lineage-negative, CD11c
þ MHCII þ cells isolated from mechanically disrupted and collagenase-digested whole nasal tissue. Three distinct populations of putative DCs could be identified using anti-CD103 and anti-CD11b antibodies: CD103 þ CD11b À cells, CD11b þ CD103 À cells, and CD103 has been shown to recognize Mf selectively 7, 26, 31, 32 and can help distinguish cDCs from Mf within CD103 À CD11b þ cells. We initially tested the expression of CD64 and heat-stable antigen or CD24, an important co-stimulatory molecule for the induction of T-helper cells, 33 on CD11c (Figure 2a) . The total number of cells contained within each of the DC subsets are quantified in Figure 2b . Next, we examined DCs in the inductive (NALT) and effector (nasal passages) sites of nose separately. As expected, the density of putative DCs was significantly greater in the NALT tissue compared with that in the nasal passages. Interestingly, the CD103 þ CD11b þ cells were predominantly found in the nasal passages, while both the NALT and non-NALT tissue contained CD103 þ CD11b À and CD103 À CD11b þ cells (Figure 2c ). Confocal images from CD11c-eYFP mice confirmed that eYFP þ DCs were present in non-NALT nasal mucosa (Figure 2d) .
A detailed phenotypic assessment of each of the putative DC subsets was performed next (Figure 2e) (Figure 2g) , consistent with the expression of epithelial cell adhesion molecule (EpCAM) by these cells, as noted by flow cytometry.
FLT3 ligand expands CD103
þ CD11b À nasal DCs and
Fms-related tyrosine 3 kinase (FLT3) ligand, a key cytokine in DC differentiation, 35 has also been used as a potent adjuvant in nasally administered vaccines. 29, 33, 36 To determine the effect of FLT3 ligand on nasal DCs, we implanted mice with 5 À 7 Â 10 6 B16-FLT3L melanoma (B16-FLT3L) cells 37 (Figure 3c) .
In order to further confirm these data, we performed additional experiments comparing the nasal populations of B16 and B16-FLT3L mice using mass cytometry (CyTOF), a novel, potentially paradigm-changing technology that combines the principles of flow cytometry with mass spectrometry, thereby allowing the simultaneous examination of significantly more variables per cell than is possible by conventional flow cytometry. 38 We analyzed nasal cell suspensions using a 20-parameter CyTOF panel focused on DC-and Mf-associated markers (Supplementary Table S4 ). We clustered DNA þ
CD45
þ events into a minimum-spanning tree of phenotypically related nodes using spanning-tree progression analysis of density-normalized events 24 ( Figure 4 ). Node clusters corresponding to definable cell populations were manually annotated on the basis of canonical marker expression, while preserving visualization of unidentified clusters within the data set. The spanning-tree progression analysis of densitynormalized event trees showed a clear and striking expansion of the CD11c-expressing DC populations following FLT3L treatment ( Figure 4a ). The expanding populations also expressed high levels of MHCII, and further delineation of the underlying phenotypic heterogeneity revealed a distribution of CD24, CD103, CD117, and CD11b expression among the expanding subsets, whereas there was no expansion in the CD64-expressing populations. For the sake of representation, only FLT3L-treated mice, focusing on putative cDC and Mf, are shown in Figure 4b . These data are summarized in Figure 4c , comparing the fold-change differences in the annotated cell populations as a percentage of total CD45 
Nasal DCs present soluble antigen to OVA-transgenic T cells and induce MLR to allogeneic T cells
Having examined the anatomical, phenotypic, morphological, and ontogenetic features of nasal ''DCs,'' we sought to use functional assays to confirm that these cells were indeed bona fide DCs. Antigen presentation to syngeneic T cells and mixed
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MucosalImmunology | VOLUME 8 NUMBER 5 | SEPTEMBER 2015 leukocyte reaction (MLR) to allogeneic T cells is among the most distinctive characteristics of DCs and distinguishes them from the closely related Mf. 42 In order to obtain sufficient numbers of cells to run functional assays and guided by the results of our FLT3L experiments, mice were implanted with B16-FLT3L melanoma cells. Nasal DCs (defined as For the antigen-presentation assays, respective cell populations were co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled ovalbumin (OVA)-transgenic (OT-II)
CD4
þ T cells in the presence OVA. To exclude the possibility that the OVA protein was degraded into peptides, which then bound spontaneously to MHCII molecules on T cells and induced T-cell proliferation, we also included a control wherein OT-II cells were cultured in the presence of OVA alone, without DCs. For MLR assays, the nasal DCs, nasal Mf, splenic DCs, and splenic B cells were cultured with CFSE-labeled BALB/c splenic T cells (as the allogeneic responders). Nasal DCs effectively stimulated allogeneic T cells similar to splenic DCs, while nasal Mf and splenic B cells were poor at inducing MLR (Figures 6a,b) . These data highlight the functional differences between CD11c
þ cells, and confirm the former to be bona fide DCs within the nose.
Nasal DCs migrate in response to LPS
Migratory behavior is a hallmark of DCs. 43 To investigate this as yet another criteria to define nasal DCs, mice were administered OVA-Alexa 488 in combination with LPS delivered intranasally. The nose and draining lymph nodes (LNs) were examined at serial time points (1, 6, 12 , and 24 h post administration). Phosphate-buffered saline (PBS)-administered mice were used as controls at each time point. In the nose, we assessed the uptake of OVA by live, CD45 þ cells and found that a minority (B3%) of OVA þ nasal cells were (Figures 7a,b) .
In parallel to the nose assessments, we also examined the draining LNs-both cervical LN (cLN) and mediastinal LN for migratory DCs (live, OVA þ lin À MHCII hi CD11c þ cells). As shown in Figure 7a and quantified in Figure 7b , a small population of OVA þ migratory DCs could be detected in the cLN at 6 h, with a progressive and striking increase at 24 h. Further analyses of these migratory DCs within the cLN revealed them to be predominantly CD11b þ CD64 À , with a small number of CD103 þ CD11b À and CD103 þ CD11b þ DCs as well, reflecting the numeric distribution of these DC subsets in the nose. As much as 40% of the OVA þ cells in the cLN at 24 h were CD11c int/ À MHC-II int/lo (Figure 7a ). However, we did not include granulocyte-specific markers in the LN panel. Therefore, we were unable to confirm whether OVA þ neutrophils also migrate into the LN. Interestingly, we did not detect OVA þ migratory DCs within the mediastinal LN even at 24 h (data not shown). Thus, we were able to demonstrate clear uptake of a fluorescent antigen by nasal DCs and their subsequent migration to the draining LN.
Next, to examine the response of nasal DCs to Gramnegative pathogens, Salmonella enterica serovar Typhimurium constitutively expressing mCherry (Salmonella-mCherry) was administered intranasally to CD11c-eYFP transgenic mice. To compare DC-associated or DC-independent clearance of Salmonella from the nose, we co-administered either PBS or pertussis toxin (PTX). The latter is a known inhibitor of DC motility. 34 Using two-photon microscopy, SalmonellamCherry were seen in the nasal cavity as early as 5 min after application, distributed within the nasal lumen (Figure 7d well as occasionally internalized within CD11c þ nasal cells (Figure 7c) . With surprising kinetics, 35 min post administration, in the PBS group, a (B50%) decline in mCherry þ cells was seen in the nose. In contrast, PTX-treated mice had a significantly greater number of mCherry þ cells compared with the nose of PBS-treated mice. This difference persisted at 12 h (Figures 7d,e) . Analogously, within the cLN, a striking increase in mCherry þ cells was seen in the PBS-treated but not PTXtreated mice at 35 min and 12 h. These data demonstrate a rapid flux of Salmonella into the draining LNs and highlights the rapid response of the antigen-presenting cells in the nose to a bacterial challenge, which is attenuated by PTX, an inhibitor of DC migration.
BDCA-1
þ DCs form the predominant DC population in human nasopharyngeal tissue at steady state and are significantly reduced during chronic inflammation
To identify nasal DCs in humans, we analyzed nasopharyngeal and sinus tissues from 10 normal volunteers (a total of 10 tissue samples) and 10 patients with CRS (a total of 21 tissue samples; Supplementary Table S1 ). The CRS patients were further divided into patients with and without nasal polyps, as these two clinical entities show distinct phenotypes, with patients having nasal polyps being more refractory to treatment. The clinical parameters that were assessed included patient age, sex, tissue analyzed, indications for surgery, and a thorough list of the concomitant medications immediately proximal to the surgery. The mean age of normal volunteers was 52 years (range 25-82), the mean age of patients with CRS was 52 years (range 40-75), while the mean age of patients with CRS/nasal polyps was 50 years (range (Figure 8a ). We observed a significantly higher frequency of BDCA-1 þ DCs rather than BDCA-3 hi DCs in normal volunteers as well as in patients with CRS. More importantly, when compared with normal volunteers, patients with CRS displayed a significantly lower frequency of BDCA-1 þ DCs (Po0.05) and a trend toward lower BDCA-3 hi DCs (P ¼ 0.07). These differences were not seen on comparing normal volunteers and patient with CRS with nasal polyps (Figure 8b ). In addition to the DC subsets described above, a detailed analysis of nasal mononuclear cells was performed. This included monocyte subsets, neutrophils, T cells, B cells, and NK cells. A decline in the BDCA-1 þ and BDCA-3 hi DCs was not accompanied by a corresponding increase in other inflammatory cells within the nose (Supplementary Figure S3 ).
DISCUSSION
Mucosal vaccination is considered to be superior to systemic vaccines for the generation of local and perhaps disseminated mucosal immune responses. Owing to its non-invasive nature and imminent antigen availability (most notably circumventing enzymatic degradation that precedes gastrointestinal mucosal absorption), i.n. antigen delivery appears to be the most feasible and clinically relevant of the various routes of mucosal vaccination and is supported by the rapid development of newer technologies to improve vaccine potency (chitosan derivatives) 44 and safety (nanogels). 45 In fact, a substantial research initiative funded by the Bill and Melinda Gates foundation focuses on the development of novel, needlefree mucosal vaccines. 37 In spite of these advances, basic descriptions of DCs in the nasal mucosa are lacking.
The observation that nasally delivered vaccines can induce antigen-specific immunity across a wide variety of systemic and mucosal sites 21 led us to hypothesize that the nasal tissue would contain a high density of DCs. In support of our hypothesis, we observed that a robust population of DCs patrols the nasal cavity, anatomically distributed in sub-epithelial, peri-vascular, and peri-lymphatic spaces, poised to respond to antigen. The latter was confirmed by the rapid kinetics of nasal DC mobilization following i.n. administration of LPS or pathogenic Gram-negative bacteria. Further, we observed nasal DCs to possess a high phenotypic diversity with distinct subsets contained within CD11c
À nasal cells are dependent on the transcription factor zbtb46 and show a preferential expansion by the cytokine FLT3L, defining these cells as ''classical DCs,'' capable of inducing a mixed leucocyte reaction and antigen presentation. In addition, these cells demonstrate classical DC morphology 43 and migrate in response to antigen. In contrast to the DCs, CD11b þ CD64 þ F4/80 þ cells in the nose did not We also document BDCA-1 þ and BDCA3 hi myeloid DCs, as well as BDCA-2 þ plasmacytoid DCs within the human nasopharyngeal tissue, and observe a decline in myeloid DCs to be associated with CRS. In light of these observations, we believe the present study to be the first comprehensive anatomic, phenotypic, ontogenic, and functional assessments of nasal DCs.
In addition to identifying distinct subsets of myeloid nasal DCs, we conclude that the CD11b þ CD64 À F4/80 À DCs comprise majority of nasal DCs. In contrast to the Peyer's patches (considered as immune inductive sites for the intestines), which have a high frequency of CD103 þ DCs, the NALT (considered as inductive immune sites for the respiratory tract) contains a low frequency of CD103 þ DCs.
þ , zbtb46 dependent and FLT3L responsive. Therefore, it would appear that the nasal cDCs are responsive to FLT3L, explaining and emphasizing the adjuvant role of FLT3L in nasally delivered vaccines. 29, 33, 36, 47 To define the anatomic relationships of nasal DCs with other cells, we have used two-and three-dimensional imaging. Twodimensional micrographs suggested a sub-epithelial location of nasal DCs, both within and extraneous to the NALT, in agreement with similar such observations. 30 Further, a dense network of CD11c hi cells, with a classical ''dendritic'' morphology was found by two-photon microscopy of the NALT with second harmonics, suggesting a lumen-oriented distribution of nasal DCs. In fact, we documented the extension of dendrites across the NALT epithelium, suggesting that nasal DCs sample the luminal contents across intact epithelium akin to the gut resident CX3CR1 þ cells. 25 In addition, we found nasal DCs to cluster around blood vessels and especially around the lymphatic channels, situated in the posterior aspects of the NALT, and speculate that in the absence of afferent lymphatics perivascular DCs are entering the NALT, while peri-lymphatic DCs are exiting it. Deeper areas within the NALT contained CD11c þ cells, albeit with a compact, rounded (as opposed to dendritic) appearance on two-photon imaging, perhaps suggesting that as the DCs contacted antigen, they became activated, lost their dendrites, and migrated deeper within the nasal tissue.
As further evidence of function, we tested for DC migration by two sets of studies. In the first, fluorescent OVA was tracked in the nasal tissues as well as draining LNs over time. A majority of the OVA þ nasal DCs (B99%) were CD103 À CD11b þ CD64 À that appeared within the cLN by 6 h and progressively increased over 12-24 h. The kinetics of response to SalmonellamCherry were, however, much different. Within 5 min of application, although a majority of the bacteria were in the nasal lumen, we could also detect Salmonellae intracellularly within the nasal CD11c þ cells. Furthermore, B50% of the administered bacteriae (10 9 cfu) were cleared from the nose within half an hour of administration and could be detected in local draining LNs by 35 min. The kinetics would suggest a DCindependent migration of Salmonellae into the draining LN. To further study this, we administered PTX, a known inhibitor of DC migration. This resulted in a significantly greater bacterial retention within the nose at 35 min and a corresponding reduction in the Salmonella count within the draining LN. This difference between PBS and PTX-administered mice persisted over 12 h. These data suggest a rapid transport of Gramnegative bacteria into the draining LN by the nasal DCs.
To lend clinical relevance to our mouse studies, we studied nasal DCs in human volunteers over a 12-month period. The goal of our human studies was to define the DC subsets in nasopharyngeal tissue and to determine whether a change in DC frequency is associated with chronic inflammation. Notably, previous studies have described human nasal DCs using a combination of HLA-DR, CD11c, and CD1c expression. 48, 49 Here, by using a detailed, 12-color flow-cytometry panel, we found that in addition to BDCA-2 þ plasmacytoid DCs, human nose biopsies encompass two other subsets of DCs: a major BDCA-1 þ population and a smaller BDCA-3 hi population. Interestingly, patients with CRS had a significantly lower frequency of BDCA-1 þ DCs than normal individuals, while the BDCA-3 hi DC reduction also trended toward statistical significance. Detailed functional or transcriptomic assessments were limited by the number of cells available to us in this study. However, in many of the human biopsy samples that we studied for DC subsets, microbial studies done as part of clinical care demonstrated a persistence of coagulase-negative staphylococci. This, combined with the observed reduction in BDCA-1 þ and BDCA-3 hi DCs in CRS, makes us hypothesize that a reduction in DCs, the key antigen-presenting cells within the nose, may predispose to impaired pathogen clearance and chronic inflammation. An alternative possibility is that nasal DCs may migrate into the draining LN during chronic inflammation, leading to falsely lowered numbers seen in the surgical specimens. 22 As obtaining tissue from patients before the onset of CRS is impossible, we are unable to test this hypothesis. Finally, although we tried to control for the effect of treatment by a careful analysis of all concomitant medications, it is likely to be that treatment may have confounding effect on our results. It is has been shown that nasal plasmacytoid DC and mDC subsets are significantly reduced following steroid use 22 and a number of patients in the CRS with nasal polyp group were treated with steroids before surgery. Regardless, further testing of the possibility that reduced nasal DC frequency may impair pathogen clearance from the nose and predispose to CRS may help identify the role of therapeutic vaccination strategies (targeting nasal DCs) to augment immune responses against specific pathogens in the treatment of patients with CRS.
To summarize, in this paper we provide the first detailed phenotypic and functional description of murine nasal DCs and describe a significant decrease in DC number to be associated with chronic naso-pharyngeal inflammation in humans. In doing so, we believe that the present study will direct the design of novel preventative and therapeutic vaccine strategies against human diseases.
METHODS
Human studies
Human nasal samples. Human nasal and nasopharyngeal tissues were obtained from patients undergoing otorhinological surgery for clinically indicated reasons at the Mount Sinai Hospital. Clinical details of the patients are listed in Supplementary Table S1 . Informed consent was obtained from the patients. All samples were collected according to protocols approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai. Analyses of human nasal DCs. The human nasopharyngeal samples were processed immediately post surgery. The tissue was minced, treated with 0.25 mg ml À 1 of collagenase (Sigma-Aldrich, St Louis, MO) at 37 1C for 60 min and cell isolation was performed. Cells were surface stained with CD45, CD20, CD3, CD335, CD66b, BDCA-1, BDCA-2, BDCA-3, CD14, and Live/Dead Fixable Blue Dead Cell Stain (Life Technologies, Grand Island, NY). Titrated antibodies were added to the cells in 50 ml PBS 1% fetal calf serum for 30 min at 4 1C. Washed cells were fixed in 2% formaldehyde and stored at 4 1C until analysis, which was performed using an LSR II flow cytometer (BD Biosciences, San Jose, CA). The whole sample was acquired and analysis was preformed using Flow Jo 9.1 software (Tree Star, Ashland, OR). To identify human DC subsets, dead cells were excluded and CD3 14 were purchased from Jackson Laboratory (Bar Harbor, ME). C57BL/6-Tg(TcraTcrb)425Cbn/J (OT-II) mice were kindly provided by Dr Shu-Hsia Chen (Mount Sinai School of Medicine). zDC DTR bone marrow chimeric mice were generously provided by Dr M.C. Nussenzweig 39 (Rockefeller University). MM DTR41 or C57BL/6 bone marrow chimeric mice were obtained from the laboratory of Dr Daniel Mucida (Rockefeller University). All animals were housed under specific pathogen-free conditions and killed at the indicated time points.
Bone marrow chimeras were created by transferring bone marrow from zDC DTR , MM DTR , and C57BL/6 mice into lethally irradiated WT C57BL/6 mice, to avoid lethality associated with DT treatments of zDC DTR or MM DTR . In brief, 7-week-old male C57BL/6 hosts underwent two treatments of 500 rads in an animal g-irradiator 3-h apart, and 2.5 Â 10 6 bone marrow cells from 8-to 12-week-old zDC DTR , MM DTR , and C57BL/6 (WT) donors, respectively, were transferred intravenously. The resulting mice (referred to herein as zDC DTR , MM DTR , and WT) were housed under specific pathogen-free conditions. The chimeric mice were fully reconstituted and ready for experimental use after 8 weeks.
Isolation of NALT. Mice were euthanized by CO 2 inhalation and an incision was made at the angle of the mouth on both sides to open the mouth and expose the palate, using established protocols. 23 Using curved fine forceps, the NALT bearing hard palate was slowly peeled and immediately embedded in to OCT (optimal cutting temperature; Sakura Finetek, Torrance, CA), and stored at À 80 1C. Nasal sections were cut at 10-mm thickness with a Leica cryostat (Leica Microsystems, Buffalo Grove, IL) and stored at À 80 1C.
Histology and immunofluorescence analysis. Nasal cryosections were stained with hematoxylin and eosin and fluorescence-activated cellsorted CD11c
þ nasal cells were centrifuged by cytospin onto glass sides, stained in Wright-Geimsa stain solution. Images were captured by brightfield microscope (Zeiss Axioplan2IE, Carl Zeiss, Thornwood, NY) and AxioVision software (Carl Zeiss). Ten-micrometer nasal sections were briefly air dried, fixed in cold acetone for 15 min, rehydrated in PBS for 10 min, blocked with 5% bovine serum albumin/0.01% Tween/PBS for 30 min at room temperature. Sections were stained in a humidified chamber for 1 or 2 h at room temperature or overnight at 4 1C with primary antibodies (Supplementary Table S2 ), washed with 0.01% Tween/PBS for 5 min three times, and stained for 1 h at room temperature with secondary antibodies. If necessary, fluorochrome-labeled tertiary antibody was applied. T cells were immunostained with rabbit anti-mouse CD3 followed by anti-rabbit IgG Alexa Fluor 488, B cells with rat anti-mouse B220 followed by anti-rat IgG Alexa Fluor 647, and DCs with hamster anti-mouse CD11c followed by both biotinylated anti-hamster IgG and streptavidin Alexa Flour 555. Epithelial cells were immunostained with rabbit anti-mouse cytokeratin 18 followed by anti-rabbit IgG Alexa Fluor 488. Endothelial cells, lining lymphatic vessels were stained with rabbit anti-mouse LYVE-1 followed by anti-rabbit IgG Alexa Fluor 488. The longitudinal sections of NALT were stained with rat anti-mouse PECAM-1 followed by anti-rat IgG Alexa Fluor 488. Sections were stained with goat anti-mouse langerin (E17) followed by donkey Two-photon microscopy. After euthanizing mice, the NALT and LNs were surgically isolated and transferred to a 25 Â 25 Â 1 mm imaging chamber (Grace Bio-Labs, Bend, OR) containing RPMI. Two-photon imaging was performed using an Olympus Fluoview FV1200MPE microscope with a 40 Â 0.8 numerical aperture water-emersion objective lens. For multiphoton excitation and second harmonic generation, a MaiTai Ti:sapphire laser (Newport/Spectra-Physics, Santa Clara, CA) was tuned to 790 and 890 nm for optimized excitation of mCherry expressing Salmonella and CD11c-eYFP þ cells, respectively. Emission filters were 420-460 for second harmonic generation (SHG), 495-540 nm for enhanced yellow fluorescent protein (eYFP), and 575-630 nm for mCherry. Six to eight 80-mm z-stacks were acquired for each NALT and two to four 200-mm z-stacks were acquired for each LN, with 2-mm z-spacing between each optical section (512 Â 512 pixels). Three-dimensional reconstruction and image analysis was performed using watershed segmentation algorithms in Imaris (Bitplane, South Windsor, CT), to quantify numbers of mCherry þ and CD11c-eYFP þ cells.
Nasal, splenic, and LN single-cell preparation. After euthanizing mice, the entire nose was dissected out using previously reported methods. 23 The organ was mechanically disrupted by using scissors and transferred to conical tubes. The tissue pieces were re suspended in 10 ml of RPMI containing 0.3 mg ml À 1 of collagenase (SigmaAldrich) and shaken at 200 r.p.m. for 60 min at 37 1C. The tissue suspension was collected and passed through a 70-mm cell strainer and the cells were pelleted by centrifugation at 1,600 r.p.m. for 5 min. The nasal cells were then resuspended in RPMI. For analyses of NALT and non-NALT DCs separately, the NALT was dissected out as mentioned in the preceding sections. The remaining nasal tissue and NALT tissue were then collagenase digested as mentioned above.
For spleen cell preparation, ACK lysis of red blood cells was followed by washing twice and filtering undigested fibrous material through a 70-mm cell strainer.
For LN single-cell preparation, LNs were isolated and mechanically disrupted. LN single-cell suspensions were prepared by incubation with 400 U ml À 1 collagenase D at 37 1C for 30 min. Cells were filtered through a 70-mm cell strainer.
Nasal DC isolation. Single-cell suspensions were isolated from the nose as described above. Using magnetic beads (Miltenyi Biotec), CD11c þ cells were isolated as previously described. 50 Briefly, the cells were washed in 1 ml of MACS buffer (Miltenyi Biotec) before 30 min incubation on ice with CD11c þ beads. The cellular suspensions were washed twice in MACS buffer and passed through a magnetic column, CD11c þ cells were isolated by positive selection, washed, and resuspended in PBS. The subsets of CD11c þ enriched cells were then sorted on FACSAria (BD Biosciences) as CD11c
Fluorescent antibodies used. We used the following murine antibodies, detailed in Supplementary Flow cytometric analyses and gating. Cells were isolated as described above. Before staining, cells were washed and resuspended in staining buffer containing 1 Â PBS, 2% bovine serum albumin, 10 mM EDTA, and 0.01% NaN 3 . To block nonspecific staining, the 2.4G2 anti-CD16/32 antibody was added. Antibodies for cell surface markers were added and cells were incubated for 25 min at 4 1C. Following the staining, the cells were washed twice and analyzed immediately or fixed in PBS containing 1% paraformaldehyde and 0.01% NaN 3 , and analyzed later on an LSR Fortessa (BD Biosciences), using multiparameter flow cytometry. For intracellular staining, post-surface staining cells were resuspended in Fixation/Permeablization solution (BD Cytofix/Cytoperm kit, BD Biosciences), and intracellular cytokine staining was performed according to the manufacturer's protocol. Flow cytometric data was analyzed with FlowJo software (Tree Star). Myeloid nasal DC cells were identified by forward and side-scatter characteristics, and dead cells were excluded using Live-dead fixable Aqua (Life Technologies) followed by sequential gating on CD45
B16-FLT3L-induced cell expansion in vivo. B16 melanoma cells (B16) and B16 melanoma cells expressing FLT3L (B16-FLT3L) were a provided by Dr Andrew Sikora. Cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and antibiotics. Mice were injected intradermally with 5-7 Â 10 6 B16 or B16-FLT3L cells. The nasal DC subsets were analyzed 10-14 days later.
Nasal sample processing by mass cytometry. The entire nose from B16 or B16-FLT3L cells implanted mice were processed as described above and stained for CyTOF analysis. All CyTOF-associated reagents were purchased from Fluidigm (Sunnyvale, CA, formerly DVS Sciences). In brief, 5 million cells were stained with a panel of 20 metal-conjugated antibodies ( Supplementary Table S4 ) for 20 min on ice. All antibodies were either purchased pre-conjugated or conjugated and validated in-house using MaxPar X8 conjugation kits, according to the manufacturer's protocols. The samples were then incubated for 5 min in cisplatin to identify dead cells, washed, and resuspended in fix/perm buffer containing Ir nucleic acid intercalator to label all nucleated cells. Immediately before analysis, the cells were washed in PBS and diH 2 0 and resuspended in diH 2 0 containing a 1:10 dilution of EQ 4 Element Calibration beads. After instrument tuning, the samples were acquired on a CyTOF2 Mass Cytometer (Fluidigm) in sequential 10-min acquisitions at a rate of o400 events per second. Following data acquisition, the FCS files were concatenated and normalized using a bead-based normalization algorithm within the CyTOF acquisition software and uploaded to Cytobank for analysis. The FCS files were manually pre-gated on Ir-193 DNA þ CD45 þ singlets excluding beads, doublets, DNA-negative cell debris, and Pt-195 cisplatin þ dead cells. The gated population was clustered using spanning-tree progression analysis of density-normalized events. 24 Cell populations on the spanning-tree progression analysis of density-normalized event trees were manually annotated and based on expression of key markers, while also preserving visualization of unidentified populations within the data set.
In vivo DT treatment. DT purchased from Sigma-Aldrich was prepared in a sterile solution of PBS at a concentration of 1 mg ml À 1 . DC depletion was effected in zDC DTR and MM DTR chimeras by a single intraperitoneal injection of 500 ng DT. In addition, WT bone marrow chimeras also received 500 ng DT per mouse. To analyze cell depletion, mice were euthanized 24 h after DT injection.
In vitro DC: T-cell co-cultures, antigen-presentation assays, and MLR. The culture medium used for DC and T-cell cultures was RPMI (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U ml À 1 penicillin, 100 mg ml LPS administration and OVA-Alexa Fluor 488. LPS of Escherichia coli was purchased from Sigma-Aldrich and prepared in a sterile solution of PBS at a concentration of 1 mg ml À 1 . OVA-Alexa Fluor 488 (Life Technologies) was reconstituted at 15 mg ml À 1 with a sterile solution of PBS. One hundred and fifty milligrams of OVA-Alexa Fluor 488 was co-administered with 1 mg of LPS in a final volume of 11 ml intranasally. Mice were killed at 1, 6, 12, and 24 h later and nasal tissues, cLN, and mediastinal LN were examined for OVA þ cells.
Infection. For mCherry expressing Salmonella infection, mice were infected intranasally with 10 9 cfu per mouse. Where specified, 1 mg PTX (List Biological Laboratories, Campbell, CA) per mouse was supplemented with Salmonella. Dr Daniel Mucida kindly provided us with mCherry expressing Salmonella. Appearance of infected mice was monitored. Cells from the nose and cervical LNs were analyzed at 5 min, 35 min, and 12 h post infection.
Statistical analysis. Data were entered into a Microsoft Excel database and Prism 6 program (GraphPad Software, La Jolla, CA) was used for quantitative data and statistical analyses. Statistical significance was evaluated using a one-way analysis of variance test followed by a posthoc Bonferroni test with a 95% confidence interval. Results are expressed as means±s.d. *Po0.05, **Po0.01, or ***Po0.001 was considered to be statistically significant.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
